{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:27:06Z","timestamp":1787671626550,"version":"build-2736575974"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,16]]},"DOI":"10.7759\/cureus.94745","type":"journal-article","created":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T21:04:01Z","timestamp":1760648641000},"source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Tofacitinib in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate: A Real-World Study"],"prefix":"10.7759","author":[{"given":"Sajid","family":"Naseem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehan","family":"Wani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jazba","family":"Yousaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammarah","family":"Amjad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeel","family":"Abbas Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miqdad","family":"Qandeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawaja","family":"Faizan Ejaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Elrefae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Iftikhar","family":"Khattak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaan A","family":"Zai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S322086","article-title":"Tofacitinib: real-world data and treatment persistence in rheumatoid arthritis","volume":"13","author":"Bertoldi I","year":"2021","unstructured":"Bertoldi I, Caporali R. Tofacitinib: real-world data and treatment persistence in rheumatoid arthritis. Open Access Rheumatol. 2021, 13:221-37. 10.2147\/OARRR.S322086","journal-title":"Open Access Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-021-02058-8","article-title":"Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review","volume":"42","author":"Dammacco R","year":"2022","unstructured":"Dammacco R, Guerriero S, Alessio G, Dammacco F. Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review. Int Ophthalmol. 2022, 42:689-711. 10.1007\/s10792-021-02058-8","journal-title":"Int Ophthalmol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: a review in rheumatoid arthritis","volume":"77","author":"Dhillon S","year":"2017","unstructured":"Dhillon S. Tofacitinib: a review in rheumatoid arthritis. Drugs. 2017, 77:1987-2001. 10.1007\/s40265-017-0835-9","journal-title":"Drugs"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2017-0118","article-title":"Tofacitinib in the treatment of active rheumatoid arthritis in adults","volume":"10","author":"Fleischmann R","year":"2018","unstructured":"Fleischmann R. Tofacitinib in the treatment of active rheumatoid arthritis in adults. Immunotherapy. 2018, 10:39-56. 10.2217\/imt-2017-0118","journal-title":"Immunotherapy"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31618-5","article-title":"Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial","volume":"390","author":"Fleischmann R","year":"2017","unstructured":"Fleischmann R, Mysler E, Hall S, et al.. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b\/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017, 390:457-68. 10.1016\/s0140-6736(17)31618-5","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224482","article-title":"Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2)","volume":"82","author":"Fleischmann RM","year":"2023","unstructured":"Fleischmann RM, van der Heijde D, Strand V, et al.. Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2). Ann Rheum Dis. 2023, 82:1516-26. 10.1136\/ard-2023-224482","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e15839","article-title":"Efficacy and safety of tofacitinib combined with methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis","volume":"9","author":"Gao Y","year":"2023","unstructured":"Gao Y, Gao YN, Wang MJ, et al.. Efficacy and safety of tofacitinib combined with methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Heliyon. 2023, 9:10.1016\/j.heliyon.2023.e15839","journal-title":"Heliyon"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24966","article-title":"Effectiveness and safety of tofacitinib in Canadian patients with rheumatoid arthritis: primary results from a prospective observational study","volume":"75","author":"Haraoui B","year":"2023","unstructured":"Haraoui B, Khraishi M, Choquette D, et al.. Effectiveness and safety of tofacitinib in Canadian patients with rheumatoid arthritis: primary results from a prospective observational study. Arthritis Care Res (Hoboken). 2023, 75:240-51. 10.1002\/acr.24966","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109095","article-title":"Advance in bone destruction participated by JAK\/STAT in rheumatoid arthritis and therapeutic effect of JAK\/STAT inhibitors","volume":"111","author":"Hu L","year":"2022","unstructured":"Hu L, Liu R, Zhang L. Advance in bone destruction participated by JAK\/STAT in rheumatoid arthritis and therapeutic effect of JAK\/STAT inhibitors. Int Immunopharmacol. 2022, 111:10.1016\/j.intimp.2022.109095","journal-title":"Int Immunopharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X231201047","article-title":"Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL surveillance","volume":"15","author":"Karpouzas GA","year":"2023","unstructured":"Karpouzas GA, Szekanecz Z, Baecklund E, et al.. Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL surveillance. Ther Adv Musculoskelet Dis. 2023, 15:10.1177\/1759720X231201047","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216656","article-title":"Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"79","author":"Kerschbaumer A","year":"2020","unstructured":"Kerschbaumer A, Sepriano A, Smolen JS, et al.. Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020, 79:744-59. 10.1136\/annrheumdis-2019-216656","journal-title":"Ann Rheum Dis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.14801","article-title":"Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: an open-label randomized controlled trial","volume":"26","author":"Khan MM","year":"2023","unstructured":"Khan MM, Ahmed S, Sajib MK, Morshed AA, Mahbub-Uz-Zaman K, Haq SA. Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: an open-label randomized controlled trial. Int J Rheum Dis. 2023, 26:1729-36. 10.1111\/1756-185X.14801","journal-title":"Int J Rheum Dis"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.977265","article-title":"Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: a systematic review and meta-analysis","volume":"13","author":"Liu L","year":"2022","unstructured":"Liu L, Yan YD, Shi FH, Lin HW, Gu ZC, Li J. Comparative efficacy and safety of JAK inhibitors as monotherapy and in combination with methotrexate in patients with active rheumatoid arthritis: a systematic review and meta-analysis. Front Immunol. 2022, 13:10.3389\/fimmu.2022.977265","journal-title":"Front Immunol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-018-1539-6","article-title":"Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study","volume":"20","author":"Machado MA","year":"2018","unstructured":"Machado MA, Moura CS, Guerra SF, Curtis JR, Abrahamowicz M, Bernatsky S. Effectiveness and safety of tofacitinib in rheumatoid arthritis: a cohort study. Arthritis Res Ther. 2018, 20:10.1186\/s13075-018-1539-6","journal-title":"Arthritis Res Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto N","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, et al.. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021, 398:1984-96. 10.1016\/s0140-6736(21)01255-1","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012657","article-title":"Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta\u2010analysis","volume":"5","author":"Singh JA","year":"2017","unstructured":"Singh JA, Hossain A, Mudano AS, et al.. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta\u2010analysis. Cochrane Database Syst Rev. 2017, 5:10.1002\/14651858.CD012657","journal-title":"Cochrane Database Syst Rev"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen JS","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RB, Bergstra SA, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023, 82:3-18. 10.1136\/ard-2022-223356","journal-title":"Ann Rheum Dis"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen JS","year":"2020","unstructured":"Smolen JS, Landew\u00e9 RB, Bijlsma JW, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020, 79:685-99. 10.1136\/annrheumdis-2019-216655","journal-title":"Ann Rheum Dis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42371-z","article-title":"Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib","volume":"13","author":"Spinelli FR","year":"2023","unstructured":"Spinelli FR, Garufi C, Mancuso S, Ceccarelli F, Truglia S, Conti F. Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib. Sci Rep. 2023, 13:10.1038\/s41598-023-42371-z","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.glmedi.2024.100118","article-title":"An autopsy presentation of spontaneous splenic rupture in chronic myeloid leukemia: a rare case report","volume":"3","author":"Kanani J","year":"2024","unstructured":"Kanani J, Sheikh MI. An autopsy presentation of spontaneous splenic rupture in chronic myeloid leukemia: a rare case report. J Med Surg Public Health. 2024, 3:10.1016\/j.glmedi.2024.100118","journal-title":"J Med Surg Public Health"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-024-00700-2","article-title":"Methotrexate, tofacitinib, and biologic disease-modifying antirheumatic drug safety and effectiveness among patients with rheumatoid arthritis in Japan: CorEvitas registry observational study","volume":"11","author":"Tanaka Y","year":"2024","unstructured":"Tanaka Y, Kishimoto M, Sonomoto K, et al.. Methotrexate, tofacitinib, and biologic disease-modifying antirheumatic drug safety and effectiveness among patients with rheumatoid arthritis in Japan: CorEvitas registry observational study. Rheumatol Ther. 2024, 11:1237-53. 10.1007\/s40744-024-00700-2","journal-title":"Rheumatol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-023-03154-z","article-title":"Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II\/III trials","volume":"25","author":"Tesser J","year":"2023","unstructured":"Tesser J, G\u00fcl A, Olech E, Oelke K, Lukic T, Kwok K, Ebrahim A. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis by previous treatment: post hoc analysis of phase II\/III trials. Arthritis Res Ther. 2023, 25:10.1186\/s13075-023-03154-z","journal-title":"Arthritis Res Ther"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1607298","article-title":"Tofacitinib for the treatment of rheumatoid arthritis: an update","volume":"15","author":"Yamaoka K","year":"2019","unstructured":"Yamaoka K. Tofacitinib for the treatment of rheumatoid arthritis: an update. Expert Rev Clin Immunol. 2019, 15:577-88. 10.1080\/1744666X.2019.1607298","journal-title":"Expert Rev Clin Immunol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg SR","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al.. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022, 386:316-26. 10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/415388-efficacy-and-safety-of-tofacitinib-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-methotrexate-a-real-world-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T21:04:01Z","timestamp":1760648641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/415388-efficacy-and-safety-of-tofacitinib-in-patients-with-rheumatoid-arthritis-and-inadequate-response-to-methotrexate-a-real-world-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,16]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.94745","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,16]]}}}